Madrigal Pharmaceuticals, Inc. (MDGL)
| Market Cap | 2.00B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -202.24M |
| Shares Out | 15.45M |
| EPS (ttm) | -13.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $124.77 |
| Previous Close | $126.65 |
| Change ($) | -1.88 |
| Change (%) | -1.48% |
| Day's Open | 126.38 |
| Day's Range | 121.94 - 128.00 |
| Day's Volume | 132,904 |
| 52-Week Range | 79.01 - 137.28 |
WEST CONSHOHOCKEN, Pa., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its fourth quarter and full year 2020 financial results and highlights.
Reddit playing a major role in biotech trading action, says Jefferies top health care analyst
Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour, Karen Fi...
The GameStop effect will soon come to biopharma, an usually heavily-shorted sector. Here's a list of three of biopharma's more heavily-shorted stocks.
In November, Madrigal released open label data from the MAESTRO-NAFLD study. This data was positive, and could be used to make predictions about the entire study.
CONSHOHOCKEN, Pa., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced that Dr. Stephen Harrison, M.D., Medical Director for Pinnacle Clinical Research, San Antonio...
CONSHOHOCKEN, Pa., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it completed enrollment in its MAESTRO NAFLD-1 clinical trial of resmetirom in pati...
When it comes to extreme wealth creation, few endeavors can compare to being an owner of a small-cap stock that grows large. The post Small-Cap Stocks Have Led Every Bull Market for Decades appeared fir...
CONSHOHOCKEN, Pa., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), announced today that, based on data from studies with MGL-3196 (resmetirom), three posters and an oral ...
CONSHOHOCKEN, Pa., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that it has already exceeded the originally targeted enrollment of 700 patients in it...
CONSHOHOCKEN, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, Eur...
CONSHOHOCKEN, Pa., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its second quarter 2020 financial results and highlights:
These two companies are going after the same target, but which one should you bet on today?
Madrigal Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Madrigal Pharmaceuticals Clears Key Benchmark, Hitting 80-Plus RS Rating appeared first on Investor's Busines...
They have one big thing in common: great growth prospects.
Madrigal's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
-- MAESTRO Phase 3 clinical studies proceed, with more flexible allowances in visits and study drug dispensing for enrolled and screened patients at impacted sites, intended to maintain patient safety a...
Madrigal: A Stellar Stock For This Coronavirus Bear Market
The U.S. Food and Drug Administration is scheduled to make decisions on five therapies in the second quarter, and the one that could make the biggest impact on the company and its shares belongs to Inte...
These companies are developing drugs that target the one of the biggest threats from the obesity epidemic.
Impressive cash position.
Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) has seen more than its share of volatility over the past year.
Madrigal: Beyond NASH
-- MAESTRO-NAFLD-1 is the second resmetirom Phase 3 clinical trial in patients with NASH and presumed NASH and follows MAESTRO-NASH, a Phase 3 multi-center, double-blind, randomized, placebo-controlled ...
WEST CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the develop...
CONSHOHOCKEN, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) (“Madrigal” or the “Company”), a clinical-stage biopharmaceutical company focused on the development ...
NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.
Data from this 36-week, multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with NASH:
CONSHOHOCKEN, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its third quarter 2019 financial results and highlights:
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.
Which of these NASH-oriented biotechs is the better buy?
Madrigal is one of the more prominent NASH-targeted biopharma companies today.
The following securities are falling knives, meaning their share prices have declined more than 59% over the last 52 weeks.
Biotech stocks Intercept Pharmaceuticals and Madrigal Pharmaceuticals were hit Thursday after the Food and Drug Administration cast doubt on a method of evaluating some liver disease drugs.
Medical technology and biotech stocks were ravaged Wednesday on a "Medicare for All" proposal out of Washington and amid rising popularity for presidential candidate Bernie Sanders.
Although possessing huge market opportunities, there is currently no ideal NASH candidate in the late clinical stage.
Liver Therapy Forum weekly digest provides an overview on what’s happening in the NASH landscape in 2019. This week focuses on Madrigal.
About MDGL
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is MGL-3196, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquar... [Read more...]
| Industry Biotechnology | Founded 2011 |
| CEO Rebecca Taub | Employees 42 |
| Stock Exchange NASDAQ | Ticker Symbol MDGL |
Analyst Forecasts
According to 16 analysts, the average rating for MDGL stock is "Buy." The 12-month stock price forecast is 171.54, which is an increase of 37.48% from the latest price.